Eric Olson, Founder and CEO
Eric Olson is CEO and founder of Babson Diagnostics. Eric previously served as VP, Portfolio & Product Management for Siemens Healthineers’ clinical laboratory business. In this role, he was globally responsible for portfolio strategy, product management, and R&D budget allocation for the company’s current and future products, including ADVIA, Centaur, Dimension, Vista, IMMULITE, and Atellica.
Eric also served as the global head of Siemens’ clinical laboratory automation and IT business, which advanced from #2 to #1 in market share during his tenure. In this role as VP, Automation & IT, he was also responsible for the company’s web properties and $1B+ in e-commerce operations.
Eric earned his Bachelor’s in Biology from the Massachusetts Institute of Technology and his Master’s in Technology Management from the University of Pennsylvania. He has a technical background in software architecture and development.
Jim Donnelly, Chief Scientific Officer & VP Laboratory Operations
Jim Donnelly is Chief Scientific Officer and Vice President of Laboratory Operations for Babson Diagnostics. Jim previously served as EVP Regulatory and Clinical Affairs for Quotient Limited and Chief Scientific Officer for at Siemens Healthineers’ Diagnostics division, where he was the Global VP for the Medical, Clinical, Scientific, and Statistical Affairs groups.
Jim is also an accomplished laboratory director and academic researcher. He was Associate Professor of Pathology at NYU School of Medicine and Associate Director of Laboratory Medicine and Pathology at New York City Health and Hospitals Corporation. In New York City, he was the Medical Director for multiple clinical pathology disciplines and CLIA high complexity laboratories across Manhattan and the Bronx.
Jim completed his Ph.D. in Pharmacology and Biochemistry at The George Washington University and his MBA from the University of Ottawa. He holds his Diplomate, Clinical Chemistry, American Board of Clinical Chemists and is a Fellow of the US National Academy of Clinical Biochemistry and the Canadian Academy of Clinical Biochemistry.
Judson Cooper, Director
Judson Cooper is a member of Babson Diagnostics’ Board of Directors and is a founding principal of Prism Ventures LLC. He has been an active investor in technology, biotechnology and healthcare companies since 1990. Along with Dr. Schein, Mr. Cooper has co-founded eight medical technology companies, serving in senior operating and advisory positions to provide financing, recruit management and oversee corporate operations and strategy. Mr. Cooper served as Chairman of SIGA Technologies and of Lev Pharmaceuticals from 2003 until its acquisition in 2008 in a transaction valued at over $500 million.
Mr. Cooper has an MBA from the Kellogg School of Management.
Joshua Schein, Director
Joshua Schein is a member of Babson Diagnostics’ Board of Directors and is a founding principal of Prism Ventures LLC. He has been involved in the formation, financing and management of biotechnology companies since 1991. Along with Mr. Cooper, Dr. Schein has co-founded eight medical technology companies. Dr. Schein has held senior operating positions in the companies he has formed, advancing innovative technologies into and through clinical development. He served as Chief Executive Officer of SIGA Technologies and Lev Pharmaceuticals.
Dr. Schein received a Ph.D. in neuroscience from the Albert Einstein College of Medicine and an MBA from the Columbia Graduate School of Business.